Allogene Therapeutics (ALLO) Shares Outstanding (2017 - 2026)

Allogene Therapeutics' Shares Outstanding history runs 10 years deep, the most recent figure standing at $244.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 11.99% year-over-year to $244.8 million; the TTM figure through Mar 2026 stood at $244.8 million (up 11.99% YoY), while the FY2025 annual figure was $229.4 million, up 8.11% from the prior year.
• Shares Outstanding came in at $244.8 million for Q1 2026 at Allogene Therapeutics, up from $229.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $244.8 million in Q1 2026 to a low of $143.6 million in Q1 2022.
• A 5-year average of $186.0 million and a median of $170.5 million in 2024 frame the typical range for Shares Outstanding.
• Across the five-year window, Shares Outstanding tumbled 84.43% in 2022 and jumped 561.49% in 2023, its largest moves.
• Allogene Therapeutics' Shares Outstanding stood at $144.4 million in 2022, then climbed by 16.76% to $168.6 million in 2023, then rose by 25.83% to $212.2 million in 2024, then climbed by 8.11% to $229.4 million in 2025, then advanced by 6.71% to $244.8 million in 2026.
• According to Business Quant data, Shares Outstanding over the past three periods registered $244.8 million, $229.4 million, and $223.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison